Ferris Capital’s TherapeuticsMD TXMD Stock Holding History

Ferris Capital’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-40	Closed	-$11K	–	536
2017 Q2	$11K	Buy	+40	New	+$10K	0.01%	454

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Ferris Capital's TXMD Position: Q3 2017 in Review

Ferris Capital sold out of TherapeuticsMD (TXMD) in Q3 2017, closing a stake of 40 shares — an estimated $11K sold.

Ferris Capital first reported a position in TXMD in Q2 2017 and held it in 1 quarter. The position peaked at $11K in Q2 2017. 134 funds tracked by Wall St. Rank hold TXMD as of Q3 2017.

Ferris Capital reported no remaining TherapeuticsMD position as of Q3 2017 after selling out during the quarter.
Ferris Capital sold 40 TherapeuticsMD shares in Q3 2017, an estimated $11K.
Ferris Capital first reported a position in TherapeuticsMD in Q2 2017 and held it in 1 quarter.
Ferris Capital's TherapeuticsMD position peaked at $11K in Q2 2017.
134 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2017.

Based on Ferris Capital's 13F filing for Q3 2017, filed 14 Nov 2017.